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Formation of CAMP has been characterised as an 
enzyme-catalysed reaction involved in the amplifica- 
tion of the chemical signals which are detected by 
various types of cell surface receptors [ 1 ] , but little 
progress has been made towards identification of 
analogous reactions linked to receptors which do not 
exert their effects through control of adenylate cyclase. 
In some cases such reactions may not exist (e.g. the 
nicotinic cholinergic receptor? [2]) but in others it 
seems more likely that they have simply eluded 
identification by the experiments done so far. In 
most investigations of receptor mechanisms emphasis 
has been placed on responses which are provoked 
maximally by low (‘physiological’) concentrations of 
agonists. We would like to suggest hat it might be 
more appropriate to concentrate on those responses 
which occur at higher, so-called ‘unphysiological’, 
agonist concentrations. This is because with many 
agonists (particularly small molecules such as 
neurotransmitters) it is necessary for only a small 
proportion of the cell’s large population of function- 
ally equivalent receptors to interact with agonist in 
order to provoke a maximal ‘physiological’ response 
such as secretion or contraction. This is thought to be 
because activation of only this small fraction of the 
total receptor population is sufficient to raise the 
intracellular concentration of a second messenger such 
as cyclic AMP or Ca*+ enough to stimulate the 
responsive enzyme(s) fully. High concentrations of 
agonists are, though, needed to bring about a maximum 
increase in the second messenger concentration. Thus, 
if the reaction which causes the change in concentra- 
tion of a second messenger (for example, adenylate 
North-Holland Publishing Company - Amsterdam 
cyclase or the mechanism which opens cell-surface 
Ca*+ gates) is directly controlled by the activated 
fraction of the receptor population then its dose- 
response curve will follow the receptor occupation 
curve, i.e. that describing the agonist-receptor interac- 
tion. In a cell responding to an agonist for.which there 
is a large population of spare receptors any reaction 
intrinsic to the mechanism which initiates amplification 
of the message received by the receptor should there- 
fore show a dose-response curve displaced to much 
higher agonist concentrations than are needed for the 
‘physiological’ responses. This general idea arises 
naturally from receptor occupation theory; it has 
already been used effectively in explaining the observed 
behaviour of receptor systems which involve control 
of adenylate cyclase and in which maximum activation 
of adenylate cyclase requires far higher agonist concen- 
trations than are needed for maximum activation of 
‘physiological’ responses [3-51. Furthermore, recent 
studies have shown that the concentration of receptors 
of a particular type can vary widely from tissue to 
tissue (and at different times in a single tissue), but that 
the dose-response relationship which describes the 
agonist-receptor interaction is essentially identical 
in all systems in which it is measured (e.g., refs. [6-81). 
As a result of the differences in receptor concentration, 
cell responses which are not directly coupled to the 
receptor vary in agonist sensitivity from tissue to tissue. 
In contrast, it is to be expected that reactions closely 
coupled to the activated receptors would vary in 
maximum response from tissue to tissue, but should 
always show dose-response curves identical with the 
receptor occupation curve: this is the pattern seen 
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with /3-adrenergically controlled adenylate cyclase 
[7,9,101. 
A potentially valuable application of these ideas, 
and one which has apparently not been explored, might 
be in screening known cell responses to stimulation in 
an attempt to detect those which show the behaviour 
to be expected of reactions intrinsic to the amplification 
stages of receptor mechanisms. We have chosen the 
specific example of the muscarinic cholinergic 
receptor to illustrate this suggestion, but the general 
method should be of wide applicability and the con- 
clusions drawn below for the muscarinic cholinergic 
receptor may also be relevant to other receptors 
which control cell-surface Ca*+ permeability. 
Various responses to stimulation of muscarinic 
cholinergic receptors are classified into five related 
groups in table 1, where the groups are arranged in an 
order which, from the information available, seems 
likely to mirror the sequence of events which occurs 
at the plasma membrane of a cell exposed to a muscari- 
nit cholinergic agonist. For the sake of simplicity the 
responses are simply described in table 1 in terms of 
the concentrations of agonists needed to elicit an 
approximately half-maximal response, even though 
in some cases the dose-response curves deviate marked- 
ly from standard mass action curves (see later). In 
group 1 are events which provide direct assessments of 
the interaction between an agonist and its binding site 
on the receptor molecule. These, which will be 
discussed further in a later section, all show somewhat 
similar dose-response relationships, with half-satura- 
tion by carbamylcholine or acetylcholine in the 
approximate range 2-20 PM. From the considerations 
above, it therefore becomes clear that we are now 
interested in finding other responses which show 
dose-response curves ,>f this general type. This 
immediately eliminates from consideration the 
‘physiological’ responses in group 5 since they occur 
at much lower (‘physiological’) agonist concentrations. 
Also in group 5, and thus eliminated, is the elevation 
in intracellular concentration of cyclic GMP which has 
recently been under consideration as a putative second 
messenger in cholinergic responses [28] : not only 
does this occur at very low agonist concentrations 
in some responsive systems, but it also shows very 
different dose-response curves to cholinergic stimula- 
tion in different experimental systems [25-271. The 
other three classes all show the required characteristic 
2 
of a half-maximal response at relatively high agonist 
concentrations, so discrimination between these 
must draw upon other considerations. Efflux of Ca*+ 
from preloaded cells, the only event in group 3, is an 
expression of increased cell permeability to this ion. 
It tells us nothing of its cause, but is useful in that it 
provides confirmation of the type of dose-response 
curve to be expected of a reaction involved in producing 
this increased permeability. In group 4 are three events, 
namely cell K’ (or Rb’) permeability, membrane conduc. 
tance and membrane depolarisation, which are 
probably all consequences of a change in cell-surface 
permeability to monovalent cations, K’ in particular 
[24]. It appears likely from studies involving Ca*’ 
depletion [29], blockade by local anaesthetics [30] and 
the use of a Ca*+ ionophore to elevate intracellular 
Ca*+ [31] that these phenomena, like those in class 5, 
are, at least in part, secondary to the increase in 
intracellular Ca*+ concentration in stimulated cells. 
The event which remains is phcsphatidylinositol 
breakdown, the one member of group 2. This is 
characterised by both a high dose-response curve 
[17-211 and an independence of extracellular Ca*+ 
[32-341, suggesting that it is not a consequence of 
Ca*+ influx into stimulated cells. This is confirmed by 
the inability of Ca*’ introduced into cells with an 
ionophore to mimic this muscarinic cholinergic re- 
spqnse [32,34] and by the inability of a variety of 
organic ‘calcium antagonists’ to prevent the phosphati- 
dylinositol response to muscarinic cholinergic stimuli 
[35]. In addition, the phosphatidylinositol response 
is widespread and it seems likely that it occurs whenever 
any tissue which possesses muscarinic cholinergic 
receptors is exposed to high concentrations of an 
agonist [21,36]. 
Phosphatidylinositol breakdown (and secondarily its 
resynthesis) is therefore the only event which, when 
triggered by the muscarinic receptor, shows the 
characteristics expected of an event that is closely 
coupled to the activated receptor and which might 
therefore be involved in an essential amplification stage 
in the receptor system. This relationship is explored 
further in fig. 1, which compares the only two 
available dose-response curves for the cholinergic 
phosphatidylinositol response with receptor occupation 
curves obtained with the same agonists: the latter are 
derived from studies of the inhibition of binding of 
propylbenzilylcholine mustard, a specific and irrever- 
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sible muscarinic antagonist, to the muscarinic receptor 
[6,13-161. It should be noted that the methods used 
for obtaining the two dose-response curves for the 
phosphatidylinositol response differed considerably: 
in fig. 1 a the quantity recorded was the incorporation 
of 32 Pi in 30 min into the phosphatidylinositol of 
fragments of guinea pig ileum smooth muscle incubat- 
ed with carbamoylcholine [20] , whereas in fig. 1 b the 
assays were of the loss in 60 min of [3H]inositol from 
the phosphatidylinositol of prelabelled mouse pan- 
creases incubated with acetylcholine [ 181. Despite 
these differences in tissue and assay procedure it is 
apparent that, at least for acetylcholine and carbamoyl- 
choline, the dose-response curves for the activation 
of phosphatidylinositol metabolism are remarkably 
similar to the receptor occupation curves. In particular, 
the phosphatidylinositol response curves resemble the 
receptor occupation curves in being markedly 
flattened relative to normal mass-action curves: the 
explanation of this is uncertain, but might involve 
either some form of negative cooperativity or the 
existence of two receptor sub-populations with 
different affinities for agonists (see ref. [6] ). The 
further prediction that for any chosen agonist the 
dose-response curve of the phosphatidylinositol 
response should be the same in all tissues cannot 
yet be tested precisely, but a review of the literature 
has already suggested that cholinergic phosphatidyl- 
inositol responses always require high agonist 
concentrations and that these concentrations always 
fall in approximately the same range [21] . 
Thus the phosphatidylinositol breakdown which is 
provoked by muscarinic cholinergic stimulation shows 
three key characteristics which might be expected of 
a reaction involved in bringing about increased cell- 
surface Ca” permeability in the stimulated cells and 
which are not exhibited by any other known response: 
(a) it shows a dose-response curve which is not typical 
for a biochemical response, but which closely follows 
the agonist-receptor interaction curve, (b) it is indepen- 
dent of changes in the intracellular Ca2+ concentration, 
and (c) it appears likely to be a universal response of 
all target cells. The idea that an enzyme reaction might 
be implicated in the mechanism of action of the 
muscarinic receptor is also favoured by the relatively 
long period of latency which intervenes between 
activation of muscarinic receptors and the detection of 
cell responses [37]. Furthermore, the occurrence of the 
phosphatidylinositol response in tissues exposed to 
other stimuli which increase cell-surface Ca2+ permea- 
bility, among them 5-hydroxytryptamine [38], a-adre- 
nergic [39-411 and Hr -histaminergic [38], emphasises 
its possible close relationship to some general mecha- 
nism for the opening of receptor-controlled cell-surface 
Ca2+ gates [21,33,35]. 
[CarbamoylcholIne], M 
b 0 
a-” P h 1 I I t 
DP 10.' O5 10.' 
[Acetylcholme]. M 
Fig.1. Comparison of dose-response curves for the phosphatidynnositol response and for muscarinic cholinergic receptor occupa- 
tion by carbamoylcholine and acetylcholine. The methods used are discussed in the text. Filled triangles denote the phosphatidyl- 
inositol response, open symbols receptor occupation measurements. Figures were calculated using information from the following 
references: fig.la (carbamoylcholine), A (20), o (14), q (15); fig.lb (acetylcholine), A (18), o (13), o (6), a (16). 
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